Abstract 59P
Background
MVX-ONCO-1 is a personalized cancer immunotherapy combining irradiated autologous tumor cells as a tailored source of antigen and cell encapsulation technology to deliver GM-CSF, a potent adjuvant, in a sustained manner. MVX-ONCO-1 Phase IIa met its primary endpoint with 68.8% patients (pts) alive at 6 months (mos). Updated median Overall Survival (OS) is 12 mos with complete and partial responses and evidence of immune education highlighted by positive Delayed Type Hypersensitivity, T and B cells responses. Safety and feasibility were assessed without any safety signals or manufacturing issues.
Methods
We analyze all 18 R/M HNSCC pts treated with MVX-ONCO-1. All had progressive disease after at least 1 line of systemic therapy, with measurable disease and ECOG PS 0-2. 15/18 pts received anti-pd-1 immunotherapy and were exposed to more than 2 lines of therapy.
Results
1 pt was lost to follow up (>14 mos), 5/17 (29.4%) are alive after 2 years and 4/16 (25%) after 3 years including 3 complete responses and 4 partial responses. To date, one pt is alive more than 7 years without any anticancer therapy and no evidence of disease. Another showed stable disease upon MVX-ONCO-1 therapy and subsequently presented a complete response upon nivolumab immunotherapy despite a PD-1 negative tumor. Based on 17 pts, median and mean survival are 21.7 mos and 33.2 mos respectively from the initiation of anti-pd-1 immunotherapy.
Conclusions
MVX-ONCO-1 is the first cancer vaccine with single agent activity, associated with prolonged survival in advanced chemotherapy / Immunotherapy refractory metastatic HNSCC without maintenance therapy. To date, second line treatment with pembrolizumab (Keynote 040) lead to 19% OS at 3 years with a median OS of 8.4 mos. First line treatment with chemotherapy / pembrolizumab (Keynote 048) shows 22% OS at 3 years and median OS of 13 mos. Data on all R/M HNSCC heavily pretreated pts treated with MVX-ONCO-1 demonstrates positive survival, with 25% of pts alive after 3 years, and median OS from start of immunotherapy reaching 21.7 mos.
Clinical trial identification
NCT02193503; NCT02999646.
Legal entity responsible for the study
Swissmedic, Geneva Ethic Committee.
Funding
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) - 880194 [Mach] Gateway for Cancer Research (Gateway) - G-15-1700 [Mach] Krebsliga Schweiz (Ligue Suisse Contre le Cancer) - KLS-3867-02-2016 [Mach] Rising Tide Foundation for Clinical Cancer research (CCR-15-140), Innosuisse (CTI), Fondation Coromandel, Philanthropy Settlement, MaxiVAX [Mach].
Disclosure
N. Mach: Financial Interests, Personal, Stocks or ownership: MaxiVAX SA. E. Charrier, J. Grogg, J. Renaux: Financial Interests, Personal, Full or part-time Employment: MaxiVAX SA. O.A. Michielin: Financial Interests, Institutional, Invited Speaker: BMS, Amgen, Pierre Fabre, Roche; Financial Interests, Institutional, Writing Engagement: BMS; Financial Interests, Institutional, Advisory Board: BMS, Amgen, Roche, Novartis, Pierre Fabre, MSD; Financial Interests, Personal, Other, Advisory Role: BMS, MSD, Roche, Novartis, Pierre Fabre, Amgen, GSL; Financial Interests, Personal, Advisory Board, Member of the Scientific Board of Cellula Therapeutics: Cellula Therapeutics; Financial Interests, Personal, Stocks/Shares: Cellula Therapeutics; Financial Interests, Institutional, Research Grant: BMS, MSD, Pierre Fabre, Amgen, Merck; Financial Interests, Institutional, Funding: BMS, MSD, Pierre Fabre, Amgen, MSD; Non-Financial Interests, Personal, Principal Investigator: BMS, MSD, Amgen, Roche, Pierre Fabre, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
Resources:
Abstract